A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist - Zoladex

A. Cassano; A. Astone; C. Garufi; M. R. Noviello; F. Pietrantonio; C. Barone

doi:10.1016/0304-3835(89)90047-5

A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist - Zoladex

A. Cassano, A. Astone, C. Garufi, M. R. Noviello, F. Pietrantonio, C. Barone

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct antitumor effect of Zoladex.

Original language	English
Pages (from-to)	123-124
Number of pages	2
Journal	Cancer Letters
Volume	48
Issue number	2
DOIs	https://doi.org/10.1016/0304-3835(89)90047-5
Publication status	Published - Nov 30 1989

Keywords

advanced breast cancer
Zoladex

ASJC Scopus subject areas

Cancer Research
Molecular Biology
Oncology

Access to Document

10.1016/0304-3835(89)90047-5

Cite this

@article{2d8e8cb151fc4b1b8b850f9b6a1d05e3,

title = "A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist - Zoladex",

abstract = "Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct antitumor effect of Zoladex.",

keywords = "advanced breast cancer, Zoladex",

author = "A. Cassano and A. Astone and C. Garufi and Noviello, {M. R.} and F. Pietrantonio and C. Barone",

year = "1989",

month = nov,

day = "30",

doi = "10.1016/0304-3835(89)90047-5",

language = "English",

volume = "48",

pages = "123--124",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist - Zoladex

AU - Cassano, A.

AU - Astone, A.

AU - Garufi, C.

AU - Noviello, M. R.

AU - Pietrantonio, F.

AU - Barone, C.

PY - 1989/11/30

Y1 - 1989/11/30

N2 - Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct antitumor effect of Zoladex.

AB - Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct antitumor effect of Zoladex.

KW - advanced breast cancer

KW - Zoladex

UR - http://www.scopus.com/inward/record.url?scp=0024433282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024433282&partnerID=8YFLogxK

U2 - 10.1016/0304-3835(89)90047-5

DO - 10.1016/0304-3835(89)90047-5

M3 - Article

C2 - 2555044

AN - SCOPUS:0024433282

VL - 48

SP - 123

EP - 124

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -

A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist - Zoladex

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this